Capricor Therapeutics (CAPR)

Executive Summary

Capricor Therapeutics is a clinical-stage biotechnology company focused on developing transformative cell and gene therapies for Duchenne muscular dystrophy (DMD) and other rare diseases. Its lead product candidate, CAP-1002, is an allogeneic cardiosphere-derived cell therapy designed to slow disease progression and improve cardiac and skeletal muscle function. In the Phase 2 HOPE-2 trial, CAP-1002 demonstrated significant improvements in upper limb function and showed a favorable safety profile, supporting advancement to pivotal studies. The company also leverages its proprietary StealthX™ exosome platform for targeted delivery, expanding its pipeline into broader cardiovascular and inflammatory indications. With a strong cash position and strategic partnerships, Capricor is well-positioned to address the high unmet need in DMD, where limited treatment options exist. The upcoming regulatory milestones and clinical data readouts are expected to be key value drivers.

Upcoming Catalysts (preview)

• Q3 2026Pivotal Phase 3 HOPE-3 trial enrollment completion and interim data70% success
• Q4 2026FDA meeting to discuss accelerated approval pathway for CAP-100260% success
• Q2 2026Preclinical data update on StealthX exosome platform for DMD80% success